Article metrics
PDF
Other content recommended for you
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Changes to anti-JCV antibody levels in a Swedish national MS cohort
- Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
- Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
- MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance
- MRI pattern in asymptomatic natalizumab-associated PML
- Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- Progressive multifocal leukoencephalopathy as the first presentation of sarcoidosis